Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …

Potentiation of glucagon-like peptide-1 (GLP-1) action through selective GLP-1 receptor
(GLP-1R) agonism or by prevention of enzymatic degradation by inhibition of dipeptidyl …

Objective Development of these guidelines is mandated by the American Association of
Clinical Endocrinologists (AACE) Board of Directors and the American College of …

Context The burden of cirrhosis from nonalcoholic fatty liver disease (NAFLD) is reaching
epidemic proportions in the United States. This calls for greater awareness among …

The burden of diabetic cardiovascular autonomic neuropathy (CAN) is expected to increase
due to the diabetes epidemic and its early and widespread appearance. CAN has a definite …

Background Semaglutide is a novel glucagon-like peptide-1 (GLP-1) analogue, suitable for
once-weekly subcutaneous administration, in development for treatment of type 2 diabetes …

Aims To compare efficacy and safety of glucagon‐like peptide‐1 receptor agonists (GLP‐
1RAs) in people with type 2 diabetes. Materials and methods We electronically searched, up …

The gastrointestinal tract—the largest endocrine network in human physiology—
orchestrates signals from the external environment to maintain neural and hormonal control …

Objective This consensus statement provides (1) visual guidance in concise graphic
algorithms to assist with clinical decision-making of health care professionals in the …

Type 2 diabetes mellitus (T2DM) is a global epidemic that poses a major challenge to health-
care systems. Improving metabolic control to approach normal glycaemia (where practical) …